DTSS$0.5901+2.63%
Datasea Intelligent Technology Ltd.
Sector: Services-Prepackaged SoftwareIndustry: Software - InfrastructureCountry: CNExchange: Nasdaq
Mkt Cap:$9.88M
Float & O/S:
Inst Own:
DilutionScan read 11 of Datasea Intelligent Technology Ltd.'s SEC filings and found 1 warrant series, 1 shelf registration and 1 completed offering on file for DTSS. The latest dilution event on file is a registration statement on Sep 8, 2026. Analysis updated Oct 14, 2026.
Signal8 Summary
15d old
DTSS
Going-concern warning, cash just $608K
- Business
- WeakGoing concern, $4.2M working-capital deficit, cash $608K
- Stock risk
- High$8.9M micro-cap, Nasdaq deficiency, shares +45.9% YoY
Snapshot
Datasea is a tiny acoustic-tech and AI agent company that shrank sharply this year: FY2026 revenue fell 43% to $40.7M after management exited lower-margin services, and the business lost $2.1M.
What's Happening Right Now
- : Datasea said service value delivered under its five AI agent customer arrangements reached about $4.0 million as of October 8, 2026, up 264% from mid-September, though the company stresses this reflects services provided, not recognized revenue, against a stated potential annualized volume of up to $89.4 million.
- : Datasea reported FY2026 revenue of $40.70M (down 43% YoY), narrowed its net loss 57% to about $2.2M, grew gross margin to 10.2%, and turned operating cash flow positive at roughly $2.0M, while also disclosing a second 180-day Nasdaq compliance period running to March 22, 2027.
- : Datasea's FY2026 20-F disclosed an auditor going-concern warning, cash of just $0.61M, a $4.20M working-capital deficit, and a $46.71M accumulated deficit, even as revenue fell 43% to $40.7M amid a deliberate pivot away from low-margin 5G services.
- : Datasea received a 180-day extension to March 22, 2027 to regain Nasdaq's $1.00 minimum bid price compliance, with the company signaling it may use a reverse stock split to cure the deficiency.
- : Registered $150.00M of securities for sale on Form F-3.
- : Datasea's NeuroVibe NV-02/NV-03 biofeedback devices completed FDA establishment registration and device listing as Class II 510(k)-exempt devices, a regulatory step short of full FDA approval.
- : Closed an offering. Proceeds are not disclosed in the filings reviewed.
- : Issued warrants over 513K shares.